HC Wainwright Estimates CareDx's Q2 Earnings (NASDAQ:CDNA)

CareDx, Inc (NASDAQ:CDNA - Free Report) - Investment analysts at HC Wainwright boosted their Q2 2025 earnings per share (EPS) estimates for CareDx in a note issued to investors on Monday, May 5th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.09) per share for the quarter, up from their previous forecast of ($0.15). HC Wainwright currently has a "Neutral" rating and a $25.00 target price on the stock. The consensus estimate for CareDx's current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for CareDx's Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.00 EPS, FY2025 earnings at ($0.33) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.16 EPS and FY2026 earnings at $0.26 EPS.

CareDx (NASDAQ:CDNA - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.03. The firm had revenue of $84.69 million during the quarter, compared to analyst estimates of $84.56 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The business's revenue for the quarter was up 17.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.03) EPS.

CDNA has been the topic of several other research reports. Wells Fargo & Company upgraded shares of CareDx from an "underweight" rating to an "equal weight" rating and dropped their target price for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th. StockNews.com lowered shares of CareDx from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Stephens reiterated an "overweight" rating and set a $40.00 target price on shares of CareDx in a research report on Monday, May 5th. Finally, The Goldman Sachs Group decreased their price target on CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $30.33.

CareDx Stock Up 0.2 %

Shares of NASDAQ CDNA traded up $0.03 during trading on Thursday, reaching $15.42. The company had a trading volume of 1,675,008 shares, compared to its average volume of 870,319. The business's 50-day moving average is $17.87 and its 200 day moving average is $21.14. The stock has a market cap of $858.60 million, a PE ratio of -5.71 and a beta of 2.27. CareDx has a 12-month low of $12.90 and a 12-month high of $34.84.

Insider Transactions at CareDx

In other news, Director Christine Cournoyer sold 16,700 shares of CareDx stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $14.13, for a total value of $235,971.00. Following the completion of the transaction, the director now owns 37,045 shares in the company, valued at approximately $523,445.85. This trade represents a 31.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Peter Maag sold 13,281 shares of the firm's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $17.23, for a total transaction of $228,831.63. Following the completion of the sale, the director now owns 316,743 shares in the company, valued at $5,457,481.89. The trade was a 4.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,246 shares of company stock worth $469,498 in the last quarter. Company insiders own 4.90% of the company's stock.

Institutional Investors Weigh In On CareDx

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in shares of CareDx by 7.1% in the fourth quarter. Vanguard Group Inc. now owns 4,859,732 shares of the company's stock valued at $104,047,000 after purchasing an additional 323,554 shares during the period. Bamco Inc. NY increased its position in CareDx by 17.6% during the fourth quarter. Bamco Inc. NY now owns 2,207,299 shares of the company's stock worth $47,258,000 after purchasing an additional 330,627 shares during the last quarter. Fred Alger Management LLC grew its position in CareDx by 7.3% during the fourth quarter. Fred Alger Management LLC now owns 1,613,992 shares of the company's stock valued at $34,556,000 after acquiring an additional 110,471 shares during the period. Invesco Ltd. grew its holdings in shares of CareDx by 3.5% during the 4th quarter. Invesco Ltd. now owns 1,514,850 shares of the company's stock worth $32,433,000 after purchasing an additional 51,160 shares during the period. Finally, Renaissance Technologies LLC raised its stake in shares of CareDx by 15.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,432,198 shares of the company's stock valued at $30,663,000 after acquiring an additional 196,298 shares during the period.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.